Home LiteratureArticle Details
PMID: 28536374 Published · epublish English Journal Article Review

Innate Lymphoid Cells in Tumor Immunity.

Biomedicines ·Vol. 4 ·No. 1 ·2016-02-25

van Beek JJP, Martens AWJ, Bakdash G, de Vries IJM

Abstract

Innate lymphoid cells (ILCs) are a group of immune cells of the lymphoid lineage that do not possess antigen specificity. The group includes natural killer (NK) cells, lymphoid tissue inducer (LTi) cells and the recently identified ILC1s, ILC2s and ILC3s. Although the role of NK cells in the context of cancer has been well established, the involvement of other ILC subsets in cancer progression and resistance is just emerging. Here, we review the literature on the role of the different ILC subsets in tumor immunity and discuss its implications for cancer treatment and monitoring.

Keywords
ILC1s ILC2s ILC3s cancer cancer immunotherapy innate lymphoid cells (ILCs) lymphoid tissue inducer (LTi) cells
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
van Beek Jasper J P
Department of Tumor Immunology, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, 6525 GA Nijmegen, The Netherlands. Jasper.vanBeek@radboudumc.nl.
Martens Anne W J
Department of Tumor Immunology, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, 6525 GA Nijmegen, The Netherlands. Anne.Martens@student.uva.nl.
Bakdash Ghaith
Department of Tumor Immunology, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, 6525 GA Nijmegen, The Netherlands. Ghaith.Bakdash@radboudumc.nl.
de Vries I Jolanda M
Department of Tumor Immunology, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, 6525 GA Nijmegen, The Netherlands. Jolanda.deVries@radboudumc.nl. | Department of Medical Oncology, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, 6525 GA Nijmegen, The Netherlands. Jolanda.deVries@radboudumc.nl.
References (116)
116 references, click to expand
  1. Intraepithelial type 1 innate lymphoid cells are a unique subset of IL-12- and IL-15-responsive IFN-γ-producing cells.
    Immunity. 2013 Apr 18;38(4):769-81 PMID: 23453631
  2. The two faces of interferon-γ in cancer.
    Clin Cancer Res. 2011 Oct 1;17(19):6118-24 PMID: 21705455
  3. IL-13Rα1 is a surface marker for M2 macrophages influencing their differentiation and function.
    Eur J Immunol. 2014 Mar;44(3):842-55 PMID: 24281978
  4. Nod/Ripk2 signaling in dendritic cells activates IL-17A-secreting innate lymphoid cells and drives colitis in T-bet-/-.Rag2-/- (TRUC) mice.
    Proc Natl Acad Sci U S A. 2014 Jun 24;111(25):E2559-66 PMID: 24927559
  5. Group 2 innate lymphoid cells and CD4+ T cells cooperate to mediate type 2 immune response in mice.
    Allergy. 2014 Oct;69(10):1300-7 PMID: 24939388
  6. Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis.
    J Clin Invest. 2008 Feb;118(2):560-70 PMID: 18219394
  7. Interleukin-22 binding protein (IL-22BP) is constitutively expressed by a subset of conventional dendritic cells and is strongly induced by retinoic acid.
    Mucosal Immunol. 2014 Jan;7(1):101-13 PMID: 23653115
  8. Interleukin-22 is frequently expressed in small- and large-cell lung cancer and promotes growth in chemotherapy-resistant cancer cells.
    J Thorac Oncol. 2013 Aug;8(8):1032-42 PMID: 23774470
  9. Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence.
    J Exp Med. 2003 Dec 1;198(11):1741-52 PMID: 14657224
  10. Identification of an interleukin (IL)-25-dependent cell population that provides IL-4, IL-5, and IL-13 at the onset of helminth expulsion.
    J Exp Med. 2006 Apr 17;203(4):1105-16 PMID: 16606668
  11. Macrophage-induced angiogenesis is mediated by tumour necrosis factor-alpha.
    Nature. 1987 Oct 15-21;329(6140):630-2 PMID: 2443857
  12. Interleukin-17 promotes angiogenesis by stimulating VEGF production of cancer cells via the STAT3/GIV signaling pathway in non-small-cell lung cancer.
    Sci Rep. 2015 Nov 03;5:16053 PMID: 26524953
  13. Microbiota-dependent crosstalk between macrophages and ILC3 promotes intestinal homeostasis.
    Science. 2014 Mar 28;343(6178):1249288 PMID: 24625929
  14. Activated group 3 innate lymphoid cells promote T-cell-mediated immune responses.
    Proc Natl Acad Sci U S A. 2014 Sep 2;111(35):12835-40 PMID: 25136120
  15. Dendritic cell cross talk with innate and innate-like effector cells in antitumor immunity: implications for DC vaccination.
    Crit Rev Immunol. 2014;34(6):517-36 PMID: 25597314
  16. TNF-alpha is critical for antitumor but not antiviral T cell immunity in mice.
    J Clin Invest. 2007 Dec;117(12):3833-45 PMID: 17992258
  17. Developing lymph nodes collect CD4+CD3- LTbeta+ cells that can differentiate to APC, NK cells, and follicular cells but not T or B cells.
    Immunity. 1997 Oct;7(4):493-504 PMID: 9354470
  18. Essential role of Stat6 in IL-4 signalling.
    Nature. 1996 Apr 18;380(6575):627-30 PMID: 8602263
  19. Tumor necrosis factor reduces brain tumor growth by enhancing macrophage recruitment and microcyst formation.
    Cancer Res. 2005 May 1;65(9):3928-36 PMID: 15867393
  20. Interleukin-5 facilitates lung metastasis by modulating the immune microenvironment.
    Cancer Res. 2015 Apr 15;75(8):1624-34 PMID: 25691457
  21. TNF-alpha regulates epithelial expression of MMP-9 and integrin alphavbeta6 during tumour promotion. A role for TNF-alpha in keratinocyte migration?
    Oncogene. 2004 Sep 9;23(41):6954-66 PMID: 15273742
  22. MHCII-mediated dialog between group 2 innate lymphoid cells and CD4(+) T cells potentiates type 2 immunity and promotes parasitic helminth expulsion.
    Immunity. 2014 Aug 21;41(2):283-95 PMID: 25088770
  23. IFN-gamma-mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer.
    Vaccine. 2010 Apr 30;28(20):3548-57 PMID: 20304037
  24. NCR(+)ILC3 concentrate in human lung cancer and associate with intratumoral lymphoid structures.
    Nat Commun. 2015 Sep 23;6:8280 PMID: 26395069
  25. CD127+ innate lymphoid cells are dysregulated in treatment naïve acute myeloid leukemia patients at diagnosis.
    Haematologica. 2015 Jul;100(7):e257-60 PMID: 25710455
  26. Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism.
    Blood. 2002 Mar 15;99(6):2114-21 PMID: 11877287
  27. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses.
    Cancer Res. 2004 Aug 15;64(16):5839-49 PMID: 15313928
  28. Human fetal lymphoid tissue-inducer cells are interleukin 17-producing precursors to RORC+ CD127+ natural killer-like cells.
    Nat Immunol. 2009 Jan;10(1):66-74 PMID: 19029905
  29. Cancer Immunosurveillance by Tissue-Resident Innate Lymphoid Cells and Innate-like T Cells.
    Cell. 2016 Jan 28;164(3):365-77 PMID: 26806130
  30. IFN-gamma-dependent inhibition of tumor angiogenesis by tumor-infiltrating CD4+ T cells requires tumor responsiveness to IFN-gamma.
    J Immunol. 2001 Feb 15;166(4):2276-82 PMID: 11160282
  31. The transcription factor T-bet regulates intestinal inflammation mediated by interleukin-7 receptor+ innate lymphoid cells.
    Immunity. 2012 Oct 19;37(4):674-84 PMID: 23063332
  32. Human innate lymphoid cells.
    Blood. 2014 Jul 31;124(5):700-9 PMID: 24778151
  33. IL-17 expression by breast-cancer-associated macrophages: IL-17 promotes invasiveness of breast cancer cell lines.
    Breast Cancer Res. 2008;10(6):R95 PMID: 19014637
  34. Tumor necrosis factor alpha as an autocrine and paracrine growth factor for ovarian cancer: monokine induction of tumor cell proliferation and tumor necrosis factor alpha expression.
    Cancer Res. 1993 Apr 15;53(8):1939-44 PMID: 8385577
  35. Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer.
    Nat Commun. 2011;2:240 PMID: 21407206
  36. CD4(+) lymphoid tissue-inducer cells promote innate immunity in the gut.
    Immunity. 2011 Jan 28;34(1):122-34 PMID: 21194981
  37. Characterization of innate lymphoid cells in human skin and blood demonstrates increase of NKp44+ ILC3 in psoriasis.
    J Invest Dermatol. 2014 Apr;134(4):984-91 PMID: 24352038
  38. Polarization of ILC2s in peripheral blood might contribute to immunosuppressive microenvironment in patients with gastric cancer.
    J Immunol Res. 2014;2014:923135 PMID: 24741632
  39. RORgammat and commensal microflora are required for the differentiation of mucosal interleukin 22-producing NKp46+ cells.
    Nat Immunol. 2009 Jan;10(1):83-91 PMID: 19029903
  40. The infiltration and functional regulation of eosinophils induced by TSLP promote the proliferation of cervical cancer cell.
    Cancer Lett. 2015 Aug 10;364(2):106-17 PMID: 25979231
  41. Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma.
    Proc Natl Acad Sci U S A. 1996 Jul 23;93(15):7673-8 PMID: 8755534
  42. Targeting natural killer cells and natural killer T cells in cancer.
    Nat Rev Immunol. 2012 Mar 22;12(4):239-52 PMID: 22437937
  43. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody.
    Blood. 2010 Sep 30;116(13):2286-94 PMID: 20460501
  44. A T-bet gradient controls the fate and function of CCR6-RORγt+ innate lymphoid cells.
    Nature. 2013 Feb 14;494(7436):261-5 PMID: 23334414
  45. Epithelial-mesenchymal transition (EMT) induced by TNF-α requires AKT/GSK-3β-mediated stabilization of snail in colorectal cancer.
    PLoS One. 2013;8(2):e56664 PMID: 23431386
  46. Hepatocellular carcinoma in cirrhosis: incidence and risk factors.
    Gastroenterology. 2004 Nov;127(5 Suppl 1):S35-50 PMID: 15508101
  47. Microbial flora drives interleukin 22 production in intestinal NKp46+ cells that provide innate mucosal immune defense.
    Immunity. 2008 Dec 19;29(6):958-70 PMID: 19084435
  48. IL-23 promotes tumour incidence and growth.
    Nature. 2006 Jul 27;442(7101):461-5 PMID: 16688182
  49. The blockade of immune checkpoints in cancer immunotherapy.
    Nat Rev Cancer. 2012 Mar 22;12(4):252-64 PMID: 22437870
  50. L-arginine availability regulates T-lymphocyte cell-cycle progression.
    Blood. 2007 Feb 15;109(4):1568-73 PMID: 17023580
  51. Tissue-infiltrating neutrophils represent the main source of IL-23 in the colon of patients with IBD.
    Gut. 2016 Oct;65(10):1632-41 PMID: 26160381
  52. Colorectal cancer and inflammatory bowel disease: epidemiology, risk factors, mechanisms of carcinogenesis and prevention strategies.
    Anticancer Res. 2009 Jul;29(7):2727-37 PMID: 19596953
  53. Synergy between CD8 T cells and Th1 or Th2 polarised CD4 T cells for adoptive immunotherapy of brain tumours.
    PLoS One. 2013 May 23;8(5):e63933 PMID: 23717511
  54. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity.
    Nature. 2010 Apr 29;464(7293):1367-70 PMID: 20200518
  55. Innate lymphoid cells promote anatomical containment of lymphoid-resident commensal bacteria.
    Science. 2012 Jun 8;336(6086):1321-5 PMID: 22674331
  56. The transcription factor GATA-3 controls cell fate and maintenance of type 2 innate lymphoid cells.
    Immunity. 2012 Oct 19;37(4):634-48 PMID: 23063333
  57. An IL-9 fate reporter demonstrates the induction of an innate IL-9 response in lung inflammation.
    Nat Immunol. 2011 Oct 09;12(11):1071-7 PMID: 21983833
  58. IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine.
    Nature. 2012 Nov 8;491(7423):259-63 PMID: 23075849
  59. Type 2 innate lymphoid cells drive CD4+ Th2 cell responses.
    J Immunol. 2014 Mar 1;192(5):2442-8 PMID: 24470502
  60. IL-12 initiates tumor rejection via lymphoid tissue-inducer cells bearing the natural cytotoxicity receptor NKp46.
    Nat Immunol. 2010 Nov;11(11):1030-8 PMID: 20935648
  61. Human type 1 innate lymphoid cells accumulate in inflamed mucosal tissues.
    Nat Immunol. 2013 Mar;14(3):221-9 PMID: 23334791
  62. IL-2: the first effective immunotherapy for human cancer.
    J Immunol. 2014 Jun 15;192(12):5451-8 PMID: 24907378
  63. Interferon--a major regulator of natural killer cell-mediated cytotoxicity.
    J Interferon Res. 1993 Aug;13(4):247-57 PMID: 7693829
  64. Interleukin-33 overexpression is associated with liver fibrosis in mice and humans.
    J Cell Mol Med. 2010 Jun;14(6B):1726-39 PMID: 19508382
  65. Biliary repair and carcinogenesis are mediated by IL-33-dependent cholangiocyte proliferation.
    J Clin Invest. 2014 Jul;124(7):3241-51 PMID: 24892809
  66. Contribution of the IL-17/IL-23 axis to the pathogenesis of inflammatory bowel disease.
    World J Gastroenterol. 2015 May 21;21(19):5823-30 PMID: 26019446
  67. An anti-tumor necrosis factor-alpha antibody inhibits the development of experimental skin tumors.
    Mol Cancer Ther. 2003 May;2(5):445-51 PMID: 12748306
  68. Functions of natural killer cells.
    Nat Immunol. 2008 May;9(5):503-10 PMID: 18425107
  69. The transcription factor GATA3 is essential for the function of human type 2 innate lymphoid cells.
    Immunity. 2012 Oct 19;37(4):649-59 PMID: 23063330
  70. Systemically dispersed innate IL-13-expressing cells in type 2 immunity.
    Proc Natl Acad Sci U S A. 2010 Jun 22;107(25):11489-94 PMID: 20534524
  71. Interleukin 23 production by intestinal CD103(+)CD11b(+) dendritic cells in response to bacterial flagellin enhances mucosal innate immune defense.
    Immunity. 2012 Feb 24;36(2):276-87 PMID: 22306017
  72. Distribution and clinical significance of Th17 cells in the tumor microenvironment and peripheral blood of pancreatic cancer patients.
    Int J Mol Sci. 2011;12(11):7424-37 PMID: 22174607
  73. L-Arginine modulates CD3zeta expression and T cell function in activated human T lymphocytes.
    Cell Immunol. 2004 Nov-Dec;232(1-2):21-31 PMID: 15922712
  74. Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161.
    Nat Immunol. 2011 Sep 11;12(11):1055-62 PMID: 21909091
  75. Functional Differences between Human NKp44(-) and NKp44(+) RORC(+) Innate Lymphoid Cells.
    Front Immunol. 2012 Apr 09;3:72 PMID: 22566953
  76. IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice.
    J Immunol. 2003 Jan 1;170(1):270-8 PMID: 12496409
  77. Immune tolerance. Group 3 innate lymphoid cells mediate intestinal selection of commensal bacteria-specific CD4⁺ T cells.
    Science. 2015 May 29;348(6238):1031-5 PMID: 25908663
  78. Interleukin-12 and -23 Control Plasticity of CD127(+) Group 1 and Group 3 Innate Lymphoid Cells in the Intestinal Lamina Propria.
    Immunity. 2015 Jul 21;43(1):146-60 PMID: 26187413
  79. Interleukin-23 is sufficient to induce rapid de novo gut tumorigenesis, independent of carcinogens, through activation of innate lymphoid cells.
    Mucosal Immunol. 2014 Jul;7(4):842-56 PMID: 24280935
  80. Innate production of T(H)2 cytokines by adipose tissue-associated c-Kit(+)Sca-1(+) lymphoid cells.
    Nature. 2010 Jan 28;463(7280):540-4 PMID: 20023630
  81. Regulated expression of nuclear receptor RORγt confers distinct functional fates to NK cell receptor-expressing RORγt(+) innate lymphocytes.
    Immunity. 2010 Nov 24;33(5):736-51 PMID: 21093318
  82. IL-22-mediated tumor growth reduction correlates with inhibition of ERK1/2 and AKT phosphorylation and induction of cell cycle arrest in the G2-M phase.
    J Immunol. 2006 Dec 1;177(11):8266-72 PMID: 17114505
  83. Differentiation of type 1 ILCs from a common progenitor to all helper-like innate lymphoid cell lineages.
    Cell. 2014 Apr 10;157(2):340-56 PMID: 24725403
  84. IL-33 promotes an innate immune pathway of intestinal tissue protection dependent on amphiregulin-EGFR interactions.
    Proc Natl Acad Sci U S A. 2015 Aug 25;112(34):10762-7 PMID: 26243875
  85. Requirement for innate immunity and CD90⁺ NK1.1⁻ lymphocytes to treat established melanoma with chemo-immunotherapy.
    Cancer Immunol Res. 2015 Mar;3(3):296-304 PMID: 25600438
  86. Group 2 innate lymphoid cells are critical for the initiation of adaptive T helper 2 cell-mediated allergic lung inflammation.
    Immunity. 2014 Mar 20;40(3):425-35 PMID: 24613091
  87. The dendritic cell system and its role in immunogenicity.
    Annu Rev Immunol. 1991;9:271-96 PMID: 1910679
  88. The inhibition of TNF-alpha anti-tumoral properties by blocking antibodies promotes tumor growth in a rat model.
    Exp Cell Res. 2007 Jul 1;313(11):2345-55 PMID: 17466973
  89. Regulation of interferon and Toll-like receptor signaling during macrophage activation by opposing feedforward and feedback inhibition mechanisms.
    Immunol Rev. 2008 Dec;226:41-56 PMID: 19161415
  90. Interferon-gamma acts directly on CD8+ T cells to increase their abundance during virus infection.
    J Exp Med. 2005 Apr 4;201(7):1053-9 PMID: 15809350
  91. CD8+ T cells circumvent immune privilege in the eye and mediate intraocular tumor rejection by a TNF-alpha-dependent mechanism.
    J Immunol. 2007 May 15;178(10):6115-22 PMID: 17475837
  92. Innate lymphoid cells--a proposal for uniform nomenclature.
    Nat Rev Immunol. 2013 Feb;13(2):145-9 PMID: 23348417
  93. IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma.
    Biochem Biophys Res Commun. 2011 Apr 8;407(2):348-54 PMID: 21396350
  94. Identification of innate IL-5-producing cells and their role in lung eosinophil regulation and antitumor immunity.
    J Immunol. 2012 Jan 15;188(2):703-13 PMID: 22174445
  95. TSLP elicits IL-33-independent innate lymphoid cell responses to promote skin inflammation.
    Sci Transl Med. 2013 Jan 30;5(170):170ra16 PMID: 23363980
  96. An essential function for the nuclear receptor RORgamma(t) in the generation of fetal lymphoid tissue inducer cells.
    Nat Immunol. 2004 Jan;5(1):64-73 PMID: 14691482
  97. Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients.
    J Hepatol. 2009 May;50(5):980-9 PMID: 19329213
  98. RORγt⁺ innate lymphoid cells acquire a proinflammatory program upon engagement of the activating receptor NKp44.
    Immunity. 2013 Jun 27;38(6):1223-35 PMID: 23791642
  99. Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model.
    J Exp Med. 2013 May 6;210(5):917-31 PMID: 23589566
  100. Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells.
    Int J Cancer. 2014 Apr 1;134(7):1669-82 PMID: 24105680
  101. Blocking retinoic acid receptor-α enhances the efficacy of a dendritic cell vaccine against tumours by suppressing the induction of regulatory T cells.
    Cancer Immunol Immunother. 2013 Jul;62(7):1273-82 PMID: 23657628
  102. Lung natural helper cells are a critical source of Th2 cell-type cytokines in protease allergen-induced airway inflammation.
    Immunity. 2012 Mar 23;36(3):451-63 PMID: 22425247
  103. IL-17 promotes tumor angiogenesis through Stat3 pathway mediated upregulation of VEGF in gastric cancer.
    Tumour Biol. 2016 Apr;37(4):5493-501 PMID: 26566627
  104. Alternative metabolic states in murine macrophages reflected by the nitric oxide synthase/arginase balance: competitive regulation by CD4+ T cells correlates with Th1/Th2 phenotype.
    J Immunol. 1998 Jun 1;160(11):5347-54 PMID: 9605134
  105. Interleukin-33-dependent innate lymphoid cells mediate hepatic fibrosis.
    Immunity. 2013 Aug 22;39(2):357-71 PMID: 23954132
  106. Endogenous IL-17 contributes to reduced tumor growth and metastasis.
    Blood. 2009 Jul 9;114(2):357-9 PMID: 19289853
  107. Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus.
    Nat Immunol. 2011 Nov;12(11):1045-54 PMID: 21946417
  108. Amphiregulin enhances regulatory T cell-suppressive function via the epidermal growth factor receptor.
    Immunity. 2013 Feb 21;38(2):275-84 PMID: 23333074
  109. Interferon gamma inhibits growth of human pancreatic carcinoma cells via caspase-1 dependent induction of apoptosis.
    Gut. 2001 Aug;49(2):251-62 PMID: 11454803
  110. Interleukin-1beta selectively expands and sustains interleukin-22+ immature human natural killer cells in secondary lymphoid tissue.
    Immunity. 2010 Jun 25;32(6):803-14 PMID: 20620944
  111. Type 2 innate lymphoid cells constitutively express arginase-I in the naive and inflamed lung.
    J Leukoc Biol. 2013 Nov;94(5):877-84 PMID: 23924659
  112. IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cells.
    J Immunol. 2010 Mar 1;184(5):2281-8 PMID: 20118280
  113. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses.
    Nat Med. 2009 Sep;15(9):1016-22 PMID: 19701202
  114. Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology.
    Nature. 2010 Apr 29;464(7293):1371-5 PMID: 20393462
  115. IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease.
    J Exp Med. 2011 Jun 6;208(6):1127-33 PMID: 21576383
  116. Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21.
    Science. 2010 May 7;328(5979):749-52 PMID: 20339029
Article Info
Journal
Biomedicines
Abbr.
Biomedicines
ISSN
2227-9059
DOI
10.3390/biomedicines4010007
Email
jasper.vanbeek@radboudumc.nl
anne.martens@student.uva.nl
ghaith.bakdash@radboudumc.nl
jolanda.devries@radboudumc.nl
Published
2016-02-25
Epub
2016-00-25
Language
English
Region
Switzerland
NLM ID
101691304
PMCID
PMC5344245
External Links
PubMed source DOI: 10.3390/biomedicines4010007 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2